DK1093370T3 - Farmaceutisk præparat til behandling af diabetes - Google Patents

Farmaceutisk præparat til behandling af diabetes

Info

Publication number
DK1093370T3
DK1093370T3 DK99957622T DK99957622T DK1093370T3 DK 1093370 T3 DK1093370 T3 DK 1093370T3 DK 99957622 T DK99957622 T DK 99957622T DK 99957622 T DK99957622 T DK 99957622T DK 1093370 T3 DK1093370 T3 DK 1093370T3
Authority
DK
Denmark
Prior art keywords
diabetes
treatment
pharmaceutical preparation
pharmaceutical
preparation
Prior art date
Application number
DK99957622T
Other languages
Danish (da)
English (en)
Inventor
Hiroyuki Odaka
Masahiro Yamane
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK1093370T3 publication Critical patent/DK1093370T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
DK99957622T 1998-06-30 1999-06-29 Farmaceutisk præparat til behandling af diabetes DK1093370T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18370098 1998-06-30

Publications (1)

Publication Number Publication Date
DK1093370T3 true DK1093370T3 (da) 2006-05-22

Family

ID=16140426

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99957622T DK1093370T3 (da) 1998-06-30 1999-06-29 Farmaceutisk præparat til behandling af diabetes

Country Status (16)

Country Link
US (2) US6329403B1 (id)
EP (1) EP1093370B1 (id)
KR (1) KR20010043455A (id)
CN (1) CN1305376A (id)
AR (1) AR019727A1 (id)
AT (1) ATE318138T1 (id)
AU (1) AU754740B2 (id)
BR (1) BR9911656A (id)
CA (1) CA2329004C (id)
DE (1) DE69929996T2 (id)
DK (1) DK1093370T3 (id)
ES (1) ES2255316T3 (id)
ID (1) ID27415A (id)
NO (1) NO20006630L (id)
WO (1) WO2000000195A1 (id)
ZA (1) ZA200006262B (id)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
WO2000078333A2 (en) 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
AU2001234114A1 (en) * 2000-02-24 2001-09-03 Takeda Chemical Industries Ltd. Drugs containing combined active ingredients
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
JP2004331500A (ja) * 2001-02-16 2004-11-25 Dainippon Pharmaceut Co Ltd 血中濃度制御製剤
US20040143015A1 (en) * 2001-03-12 2004-07-22 Villhauer Edwin Bernard Combination of organic compounds
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US20070203225A1 (en) * 2001-04-03 2007-08-30 Havel Peter J Method of increasing endogenous adiponectin production and leptin production
US20030008838A1 (en) * 2001-04-03 2003-01-09 Havel Peter J. Method of increasing endogenous leptin production
US20050261362A1 (en) * 2004-03-22 2005-11-24 The Regents Of The University Of California Method of increasing endogenous adiponectin and leptin production
JP2002360666A (ja) * 2001-06-11 2002-12-17 Takeda Chem Ind Ltd コバルト合金を用いた打錠用杵臼
WO2003059378A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
US7101845B2 (en) * 2002-01-31 2006-09-05 Joslin Diabetes Center, Inc. Methods of modulating β cell function
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
EP1388352A1 (en) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004078717A1 (en) * 2003-03-03 2004-09-16 Merck & Co., Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
US20050187266A1 (en) * 2003-04-15 2005-08-25 Pfizer Inc Alpha substituted carboxylic acids
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US7008957B2 (en) * 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CA2545719A1 (en) * 2003-11-14 2005-06-02 Vertex Pharmaceuticals Incorporated Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
US20090111742A1 (en) * 2004-01-26 2009-04-30 Alexei Kharitonenkov Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
GB2435770B (en) * 2004-12-03 2010-05-05 Vetco Gray Scandinavia As Hybrid control system and method
KR100697982B1 (ko) * 2005-07-08 2007-03-23 대봉엘에스 주식회사 로시글리타존의 제조방법
KR100697983B1 (ko) * 2005-07-08 2007-03-23 대봉엘에스 주식회사 신규 중간체 및 이를 이용한 피오글리타존의 제조방법
US20070129444A1 (en) * 2005-12-06 2007-06-07 Mallinckrodt Inc. Novel weight reduction composition and uses thereof
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2008091624A2 (en) * 2007-01-22 2008-07-31 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
KR101263225B1 (ko) * 2007-03-30 2013-05-13 티오가 파마슈티칼스, 인코포레이티드 설사－우세형 및 교대형 과민성 장 증후군의 치료를 위한 카파－아편제 작용제
US20090318520A1 (en) 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
ES2533601T3 (es) * 2010-11-03 2015-04-13 Arecor Limited Nueva composición que comprende glucagón
PL2916852T3 (pl) * 2012-11-06 2021-11-02 Sigrid Therapeutics Ab Porowaty materiał z krzemionki do stosowania jako farmaceutyczny lub dietetyczny składnik czynny
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030174C (en) 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
GB9111426D0 (en) * 1991-05-28 1991-07-17 Ici Plc Chemical compounds
WO1993003724A1 (en) 1991-08-26 1993-03-04 The Upjohn Company Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ES2241036T3 (es) * 1996-02-02 2005-10-16 MERCK & CO., INC. Procedimiento de tratamiento de diabetes y estados patologicos asociados.
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
CN1305376A (zh) 2001-07-25
AR019727A1 (es) 2002-03-13
NO20006630L (no) 2001-02-26
EP1093370A1 (en) 2001-04-25
ATE318138T1 (de) 2006-03-15
ZA200006262B (en) 2001-11-02
CA2329004A1 (en) 2000-01-06
US20020086885A1 (en) 2002-07-04
DE69929996T2 (de) 2006-11-16
EP1093370B1 (en) 2006-02-22
AU754740B2 (en) 2002-11-21
ID27415A (id) 2001-04-05
WO2000000195A1 (en) 2000-01-06
ES2255316T3 (es) 2006-06-16
DE69929996D1 (de) 2006-04-27
CA2329004C (en) 2009-04-14
BR9911656A (pt) 2001-03-20
US6329403B1 (en) 2001-12-11
KR20010043455A (ko) 2001-05-25
AU4291499A (en) 2000-01-17
NO20006630D0 (no) 2000-12-22

Similar Documents

Publication Publication Date Title
DK1093370T3 (da) Farmaceutisk præparat til behandling af diabetes
DK0941103T3 (da) Farmaceutisk præparat til behandling af diabetes
DK1196163T3 (da) Farmaceutiske sammensætninger til behandling af insulinresistens
DK1158992T3 (da) Anvendelse af xenon til fremstilling af et farmaceutisk præparat til behandling af neurointoksikationer
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1275387T3 (da) Fremgangsmåde til fremstilling af farmaceutiske præparater af fenofibrat med höj biologisk tilgængelighed
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK2412368T3 (da) Sammensætning til behandling af ar
DK1196172T3 (da) (S,S)-reboxetin til behandling af kronisk smerte
DK0956858T3 (da) Farmaceutiske præparater indeholdende lactobacilli til behandling af vaginale infektioner
PT1066027E (pt) Composicao farmaceutica de topiramato
DK1173431T4 (da) Fremgangsmåde til fremstilling af citalopram
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
DK1105382T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1159274T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK1165576T3 (da) Fremgangsmåde til fremstilling af amin-platin-komplekser
DK1466615T3 (da) Farmaceutisk præparat
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
DK1150991T3 (da) Præparater til behandling af inflammatoriske reaktioner
DK0979079T3 (da) Anvendelse af tetrahydropyridinderivater til fremstilling af lægemidler til behandling af sygdomme, der medförer en demyelinisering
PT1154777E (pt) Medicamento para o tratamento de hipertensao arterial
NO20005179D0 (no) Medikament behandling
DK199800837A (da) Anlæg til behandling af emner
NO20014926D0 (no) Farmasöytiske forbindelser